Theraclion : AGM 2024 Présentation

Assemblée Générale

Yann Duchesne

Martin Deterre

Ling Ling Chea

Malakoff, 18 juin 2024

Déroulé de l'Assemblée Générale Mixte

Malakoff, le 18 juin 2024

• Ouverture de l'assemblée par le Président
• Constitution du bureau
• Annonce du quorum
• Présentation de l'activité au cours de l'exercice clos le 31 décembre 2023
• Présentation des comptes de l'exercice clos le 31 décembre 2023
• Présentation des rapports du commissaire aux comptes
• Présentation des résolutions
• Clôture de l'assemblée

2 © 2024 Theraclion

Management

Présentation de l'activité

Martin Deterre

LAST 12 MONTHS ACHIEVEMENTS

ON THE 3 STRATEGIC AXES

US Access

FDA feasibility study: Success, 95% efficacy

• FDA pivotal study:
  o Started on time in Oct 23
  o Currently on time for last treatment by mid-2024
  o Follow-upper plan

China Access

• First class Chinese strategic partner chosen (Furui)
• Partnership framed
• JV structured, team built up
• 1st prototype manufacturing ongoing

Product dev. in EU

• 2500+ treatments
• Commercial relationships with KOL steady
• Tier-1sites at 100 or 150 treatments per year already
• Publication out with 98%+ efficacy
• KOL presentations

2023 : 12 events, 10 speakers,

7 countries

2024 YTD : 14 events, 9 speakers, 8 countries

• R&D:

1. HD23 version out, in trial

1. Strong progress in acoustics, robotics, AI, Reliability ++

4 © Theraclion - Confidential

Management

Présentation de l'activité

Martin Deterre

VARICOSE VEINS: A WIDESPREAD CONDITION

WHAT ARE VARICOSE VEINS?

Varicose veins are swollen, twisted subcutaneous veins of the lower leg

Inadequacy of the valves results in reflux of blood in the veins

ONE IN THREE ADULTS

31% of adults aged 18 to 64 are affected by varicose veins

Source: Austin Vein Specialists

Source: Maurins et al., 2008

6	© Theraclion - Confidential

SONOVEIN®, A NEW ROBOTIC SOLUTION

	Robotic treatment head
	with in-line visualization
	Robotized
	head
	Consumable:
Real-time	Cooling and coupling
Technology (through
ultrasound	Epack )
visualization and
control	Ultrasound imaging probe
Présentation avec multimédia avec un remplissage uni		Epack
	HIFU transducer
	Millimetric treatment accuracy

Video link

INTELLECTUAL PROPERTY

Patents : 164 granted, 211 filed, 30 families in HIFU procedure safety & efficacy, system design and application

8	© Theraclion - Confidential

VARICOSE VEINS: A MULTIBILLION $ MARKET POTENTIAL

ALIGNED WITH CURRENT MARKET TRENDS

$13B

Current medical costs for varicose vein treatments worldwide

5M+

Annual addressable procedures

Up to 50%

Sonovein device cost per procedure

vs:

• Stripping: 1-2%
• Endovenous: 10-15%

SIGNIFICANT GROWTH

DRIVERS AND OPPORTUNITIES

• 6,5% annual growth in varicose
  veins patients driven by

Age Obesity Lifestyle

• 54% of undiagnosed patients in
  industrialized countries
• Largely unmet medical need in

emerging countries + China

• 50% of people afraid of surgery

untapped patient pool for

Sonovein

9	Sources: 1) Millenium studies US 2015-EU 2020 2) Vuylsteke 2015 , Eur J Vasc Endovasc Surg (2015) 49, 432e439 3) Abate, International Journal of Surgery Open 25 (2020) 6e16	© Theraclion - Confidential
4) Theraclion estimations

NEW BUSINESS MODEL, PAY-PER-USE

RECURRING REVENUES YEAR ON YEAR VERSUS 1-OFF REVENUES

DIRECT SALES*	PAY-PER-USE
Capital equipment	Paying consumables
+
only
Consumables
+	(w/ monthly min. quantity)	OUR CONSUMABLE
Service	Single-useEPack :
		ensures cooling and
		coupling

• To medical centers, hospitals, clinics

10	© Theraclion - Confidential